Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2022 |
Apr. 08, 2022 |
Nov. 19, 2020 |
Dec. 12, 2019 |
Dec. 12, 2019 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Dec. 31, 2021 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Revenue | $ 1,063 | $ 1,096 | $ 2,125 | ||||||||
| BioNTech Agreement [Member] | |||||||||||
| Fees received | $ 2,750 | ||||||||||
| Revenue recognized | $ 688 | $ 2,750 | $ 688 | ||||||||
| Revenue | $ 375 | ||||||||||
| CFF Agreement [Member] | |||||||||||
| Grants receivable | 3,600 | 3,600 | |||||||||
| Additional milestone payment | 4,500 | 4,500 | |||||||||
| CFF Agreement [Member] | Accrued Liabilities [Member] | |||||||||||
| Other Liabilities | $ 88 | $ 0 | $ 0 | ||||||||
| CFF Agreement [Member] | Cystic Fibrosis Foundation [Member] | |||||||||||
| Therapeutics development award | $ 4,200 | ||||||||||
| Proceeds from award | $ 484 | ||||||||||
| Additional milestone payment | $ 321 | ||||||||||
| Genentech Feasibility Study Agreement [Member] | Genentech [Member] | |||||||||||
| Revenue | $ 33 | ||||||||||
| Agreement description | Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement. | ||||||||||
| Aggregate revenue | $ 100 | ||||||||||
| X | ||||||||||
- Definition Additional milestone payment. No definition available.
|
| X | ||||||||||
- Definition Agreement description. No definition available.
|
| X | ||||||||||
- Definition Commitment payment. No definition available.
|
| X | ||||||||||
- Definition Proceeds from award. No definition available.
|
| X | ||||||||||
- Definition Therapeutics development award. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Cash received for fees during the current period. This element excludes cash proceeds from license fees. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|